



NOV 3 2006

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

W.L. Gore & Associates, Inc.  
% Mr. Timothy W. Capehart  
Regulatory Affairs Associate  
3450 West Kiltie Lane  
P.O. Box 2400  
Flagstaff, Arizona 86003

Re: K024178

Trade/Device Name: VIATORR<sup>®</sup> Endoprosthesis  
Regulation Number: 21 CFR 878.3720  
Regulation Name: Tracheal prosthesis  
Regulatory Class: II  
Product Code: JCT  
Dated: December 16, 2002  
Received: December 18, 2002

Dear Mr. Capehart:

This letter corrects our substantially equivalent letter of March 7, 2003.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 - Mr. Timothy W. Capehart

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Mark N. Melkerson

Director

Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

510(k) Number (if known) : **K024178**

Device Name : VIATORR® Endoprosthesis

Indications for Use:

The VIATORR® Endoprosthesis is indicated for the treatment of tracheobronchial strictures produced by malignant neoplasms.

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED.)

Concurrence of CDRH, Office of Device Evaluation (ODE)



**(Division Sign-Off)**

**Division of General, Restorative  
and Neurological Devices**

Prescription Use   
(Per 21 CFR 801.109)

Over-the-Counter Use

510(k) Number K024178

### Premarket Notification Summary

1. **Applicant Name, Address:** W.L. Gore & Associates, Inc.  
3450 W. Kiltie Lane  
P.O. Box 500  
Flagstaff, AZ 86002-0500  
  
**Contact Person:** Timothy W Capehart  
(928)864-3719  
  
**Date of Summary:** December 16, 2002  
Revised August 28, 2006
2. **Classification Name:** Tracheal prosthesis  
  
**Common or Usual Name:** Tracheobronchial stent  
  
**Trade or Proprietary Name:** VIATORR™ Endoprosthesis
3. **Device Predicates:** VIABAHN™ Endoprosthesis, Ultraflex™ Tracheobronchial Stent System, and WALLGRAFT® Tracheobronchial Endoprosthesis with Unistep Plus Delivery System.
4. **Device Description:** The VIATORR Endoprosthesis is a self-expanding implantable endoprosthesis that is compressed and secured on the distal end of a catheter delivery system. The catheter delivery system provides a means for implanting the endoprosthesis at a target location within the tracheobronchial tract. The endoprosthesis consists of a fluoropolymeric tube with a nitinol structure located over its external surface and radiopaque markers. The catheter delivery system is configured with radiopaque markers and is designed for use with guidewires.

5. **Intended Use:** The VIATORR Endoprosthesis is indicated for the treatment of tracheobronchial strictures produced by malignant neoplasms.
  
6. **Substantial Equivalence:** A variety of tests, assessments, and comparisons demonstrate that the VIATORR Endoprosthesis is substantially equivalent to the cited predicates in terms of composition, design, intended use, and performance attributes.